EVGN Evogene
- 4.8400
- -1.0450-17.76%
Evogene News
Express News | Trading Halt: Halted at 7:50:00 P.m. ET - Trading Halt: Halt News Pending
Evogene To Carry Out 1-for-10 Reverse Stock Split On July 25th, 2024
Express News | Evogene Shares Are Trading Lower After the Company Announced a 1-for-10 Reverse Share Split
Evogene Set to Implement 1-for-10 Reverse Split of Common Stock; Shares Fall
Express News | Evogene Announces Expected Implementation of 1-for-10 Reverse Share Split
Evogene Announces 1-for-10 Reverse Stock Split
ICL, Lavie Bio Say AI Collaboration Has Helped in Search for Crop Bio-Stimulants
ICL And Lavie Bio Leverage AI To Make Significant Advancement In Development Of Yield Increasing Bio-Stimulants
ICL and Lavie Bio Leverage Artificial Intelligence to Make Significant Advancement in Development of Yield Increasing Bio-Stimulants
Lavie Bio Announces Commercial Expansion of YalosTM to Winter Wheat
A. G. P. Initiates Evogene(EVGN.US) With Buy Rating, Announces Target Price $2.25
Evogene Subsidiary Casterra Ag Expands Into Africa With $440K Castor Seed Order
Casterra Announces an Additional Purchase Order to Supply Castor Seeds to a New African Country
Evogene Innovates With AI in Life-Sciences
Earnings Call Summary | Evogene(EVGN.US) Q1 2024 Earnings Conference
Express News | Biomica Announces Encouraging Initial Findings From Phase 1 Clinical Trial Of BMC128, Its Microbiome-Based Immuno-Oncology Candidate, In Combination With Nivolumab For Patients With NSCLC, Melanoma, Or RCC
Biomica Presents Positive Clinical Data Update From Ongoing Phase 1 Trial of Microbiome-Based Therapeutic, BMC128, for Refractory RCC, NSCLC & Melanoma
Lake Street Maintains Evogene(EVGN.US) With Buy Rating, Maintains Target Price $3
Evogene's Strategic Growth Boosts Q1 2024 Results
Express News | Evogene Q1 2024 GAAP EPS $(0.08) Beats $(0.09) Estimate, Sales $4.190M Beat $3.500M Estimate
Analysis
Price Target
No Data
